Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD

Key Points

• 33.7% stake cut: Mitsubishi UFJ Trust & Banking sold 451,077 Gilead shares in Q4 and now holds 888,971 shares valued at about $109.12 million (≈0.07% of the company).
• Insider selling activity: Two insiders (Johanna Mercier and CFO Andrew D. Dickinson) each sold 3,000 shares on April 15 under Rule 10b5‑1, and insiders have sold 178,640 shares (~$26.7M) in the past three months, now owning 0.30% of Gilead.
• Analyst and company fundamentals: Analysts show a consensus "Moderate Buy" (24 Buys, 4 Holds) with an average price target of $157.35 after Gilead beat Q results; the company raised its quarterly dividend to $0.82 (2.6% yield) and set FY26 EPS guidance of $8.45–$8.85.

Mitsubishi UFJ Trust & Banking Corp reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 888,971 shares of the biopharmaceutical company's stock after selling 451,077 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.07% of Gilead Sciences worth $109,116,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in GILD. Brighton Jones LLC grew its stake in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $215,000. Sivia Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC lifted its holdings in shares of Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock worth $13,160,000 after purchasing an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC boosted its position in Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock valued at $516,000 after buying an additional 674 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the insider directly owned 128,779 shares of the company's stock, valued at $18,152,687.84. The trade was a 2.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the sale, the chief financial officer owned 176,191 shares of the company's stock, valued at $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 178,640 shares of company stock worth $26,691,550. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. TD Cowen increased their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a "buy" rating in a report on Wednesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Saturday, March 14th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $157.35.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $127.75 on Tuesday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm has a fifty day moving average of $141.90 and a 200 day moving average of $132.30. The firm has a market cap of $158.57 billion, a PE ratio of 18.87, a PEG ratio of 1.72 and a beta of 0.39. Gilead Sciences, Inc. has a one year low of $95.29 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.